Dong, Yizhou - The Ohio State University

个人简介

Yizhou Dong is an Associate Professor in the Division of Pharmaceutics and Pharmacology, College of Pharmacy at The Ohio State University. He received his B.S. in pharmaceutical sciences from Peking University, Health Science Center and M.S. in organic chemistry from Shanghai Institute of Organic Chemistry. In 2009, he received his Ph.D. degree in pharmaceutical sciences from the University of of North Carolina at Chapel Hill (UNC-CH) under the supervision of Professor K.-H. Lee. From 2010 to 2014, he was a postdoctoral fellow in the laboratory of Professors Robert Langer and Daniel Anderson at Harvard Medical School and Massachusetts Institute of Technology. His research focuses on the design and development of biotechnology platforms for the treatment of genetic disorders, infectious diseases, and cancers. Dr. Dong has authored over sixty papers and over thirty patents. Several of his inventions have been licensed and are currently under development as drug candidates for clinical trials. Dr. Dong is the recipient of Young Innovator in Cellular and Molecular Bioengineering from the Biomedical Engineering Society, Maximizing Investigators’ Research Award from the National Institute of General Medical Sciences (NIGMS), Ohio State Early Career Innovator of the Year, and The American Association of Pharmaceutical Scientists (AAPS) Emerging Leader Award. 2014- Postdoctoral Fellow, Drug Delivery and RNA Therapeutics, Massachusetts Institute of Technology & Harvard Medical School 2009- PhD, Medicinal and Pharmaceutical Chemistry, University of North Carolina at Chapel Hill 2005- MS, Organic Chemistry, Shanghai Institute of Organic Chemistry 2002- BS, Pharmaceutical Science, Peking University

研究领域

Cell-specific and multifunctional drug delivery in vivo has been regarded as one of the most challenging issues in the field of drug delivery. A wide variety of cell types in humans still cannot be efficiently and specifically reached by delivery systems such as lung epithelial cells, metastatic tumor cells, and immune cells. An even more formidable task is delivering multiple payloads into specific cells and tissues. To address these challenges, my laboratory-Drug Discovery and Delivery Laboratory focuses on the following research areas: 1) to develop cell specific drug delivery systems; 2) to construct multifunctional drug delivery systems; 3) to demonstrate therapeutic efficacy of these systems in animal models for treating genetic disorders, infectious diseases, as well as cancers.

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Li, W., Zhang, X., Zhang, C., Yan, J., Hou, X., Du, S., Zeng, C., Zhao, W., Deng, B., McComb, D., Zhang, Y., Kang, D., Li, J., Carson, W., Dong, Y.*, Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapy, Nature Communications, 12-7264 (2021). Wang, C., Zhang, Y., Dong, Y.*, Lipid Nanoparticle–mRNA Formulations for Therapeutic Applications, Accounts of Chemical Research, 1c00550 (2021). PMID: 34793124 Yan, J., Kang, D., Turnbull, G., Dong, Y.*, Delivery of CRISPR-Cas9 system for screening and editing RNA binding proteins in cancer, Advanced Drug Delivery Reviews, 114042 (2021). PMID: 34767864 Zhao, W., Zeng, C., Yan, J., Shi, D., Hou, X., Zhang, C., Li, W., Deng, B., McComb, D., Xue, Y., Kang, D., Dong, Y.*, Construction of Messenger RNA (mRNA) Probes Delivered By Lipid Nanoparticles to Visualize Intracellular Protein Expression and Localization at Organelles, Advanced Materials, 2103131 (2021). PMID: 34541724 Hou, X., Zaks, T.*, Langer, R.*, Dong, Y.*, Lipid nanoparticles for mRNA delivery, Nature Reviews Materials, (2021). PMID: 34394960 Zhang, Y., Sun, C., Wang, C., Jankovic, K., Dong, Y.*, Lipids and Lipid Derivatives for RNA Delivery, Chemical Reviews, (2021). PMID: 34279087 Yan, J., Kang, D., Dong, Y.*, Harnessing lipid nanoparticles for efficient CRISPR delivery, Biomaterials Science, 06-11 (2021). PMID: 34115079 Zeng, C., Hou, X., Bohmer, M., Dong, Y.*, Advances of nanomaterials-based strategies for fighting against COVID-19, View, 20200180 (2021). PMID: 34766161 Chan, C., Du, S., Dong, Y.*, Cheng, X*., Computational and Experimental Approaches to Investigate Lipid Nanoparticles as Drug and Gene Delivery Systems, Current Topics in Medicinal Chemistry, 21(2):92-114 (2021). PMID: 33243123 Zhang, S., Shrestha, C., Wisniewski, B., Pham, H., Hou, X., Li, W., Dong, Y., Kopp, B*., Consequences of CRISPR-Cas9-Mediated CFTR Knockout in Human Macrophages, Frontiers in Immunology,11:1871 (2020). PMID: 32973772 Zeng, C., Hou, X., Yan, J., Zhang, C., Li, W., Zhao, W., Du, S., Dong, Y.*, Leveraging mRNA Sequences and Nanoparticles to Deliver SARS-CoV-2 Antigens In Vivo, Advanced Materials, 2004452 (2020). PMID: 32875709 Zhang, X., Zhao, W., Nguyen, G., Zhang, C., Zeng, C., Yan, J., Du, S., Hou, X., Li, W., Jiang, J., Deng, B., McComb, D., Dorkin, R., Shah, A., Barrera, L., Gregoire, F., Sign, M., Chen, D*., Sabatino, D*., Dong, Y.*, Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing, Science Advances, 6.34 (2020). PMID: 32937374 Li, Y., Su, Z., Zhao, W., Zhang, X., Momin, N., Zhang, C., Wittrup, K., Dong, Y.*, Irvine, D*., Weiss, R*.,Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity, Nature Cancer, 10.1038 (2020). PMID: 34447945 Zeng, C., Zhang, C., Walker, P., Dong, Y.*, Formulation and Delivery Technologies for mRNA Vaccines, Current Topics in Microbiology and Immunology, 10.1007 (2020). PMID: 32483657 Zhao, P., Zhang, Y., Li, W., Jeanty, C., Xiang, G*., Dong, Y.*, Recent advances of antibody drug conjugates for clinical applications, Acta Pharmaceutica Sinica B, 04-012 (2020). PMID: 33088681 Zhao, P., Hou, X., Yan, J., Du, S., Xue, Y., Li, W., Xiang, G.*, Dong, Y.*, Long-term storage of lipid-like nanoparticles for mRNA delivery, Bioactive Materials, 5 (2): 358-363 (2020). PMID: 32206737 Li, W., Chan, C., Zeng, C., Turk, R., Behlike, M., Cheng, X*., Dong, Y.*, Rational Design of Small Molecules to Enhance Genome Editing Efficiency by Selectively Targeting Distinct Functional States of CRISPR-Cas12a, Bioconjugate Chemistry, 18:31(3):542-546 (2020). PMID: 32119776 Guo, S., Vieweger, M., Zhang, K., Yin H., Wang, H., Li, X., Li, S., Hu, S., Sparreboom, A., Evers, B., Dong, Y., Chiu, W., Guo, P.*,Ultra-thermostable RNA Nanoparticles for Solubilizing and High-yield Loading of Paclitaxelfor Breast Cancer Therapy, Nature Communication, 11:972 (2020). PMID: 32080195 Li, B., Yan, J., Zhang, Y., Li, W., Zeng, C., Zhao, W., Hou, X., Zhang, C., Dong, Y.*, CRISPR-Cas12a Possess Unconventional DNase Activity that Can Be Inactivated by Synthetic Oligonucleotides, Molecular Therapy-Nucleic Acids, 19:1043-1052 (2020). PMID: 32045875 Hou, X., Zhang, X., Zhao, W., Zeng, C., Deng, B., McComb, D. W., Du, S., Zhang, C., Li. W., Dong, Y.*, Vitamin lipid nanoparticles enable adoptive macrophage transfer for the treatment of multidrug-resistant bacterial sepsis, Nature Nanotechnology, 15(1):41-46 (2020). PMID: 31907443